ZTS · 10-Q · 2026Q2 · Full report

Product Launch and Transition

Zoetis Inc. · 2026-08-06 · Importance 38 · Surprise 60

Zoetis launched Lenivia and Portela in international markets as long-acting monoclonal antibody pain products. The launches contributed to increased demand for small animal diagnostics and monoclonal antibody pain products during the quarter. International companion animal operational revenue also benefited from increased sales of the parasiticides portfolio. Growth was partly offset by decreased sales of key dermatology products.

Key facts

• The company's parasiticides portfolio and small animal diagnostics and mAb pain products (Lenivia and Portela) contributed to companion animal operational revenue growth in International in the three months ended June 30, 2026, partially offset by decreased sales of key dermatology products. source
• The MFA divestiture reduced volume by approximately 1% for the three months ended June 30, 2026. source